{"member_organisations": "", "identification_number": "260256215861-19", "fields_of_interest": "Humanitarian aid and civil protection, Research and innovation, Public Health", "head_office_address": "Erika-Mann-Str. 21", "full_time_equivalent_fte": "1", "person_with_legal_responsibility": "Robert Dornheim", "industry_forums": "", "grants": "", "country_code": "de", "inter_groups": "", "eu_initiatives": "Rapid and equitable access to pharmaceuticals", "level_of_interest": "global", "organisation_name": "Otsuka Novel Products GmbH (ONPG)", "belgium_office_post_code": "", "number_of_persons_involved": "4", "person_in_charge_of_eu_relations": "Robert Dornheim", "section": "II - In-house lobbyists and trade/business/professional associations", "lon": "11.5434995", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "", "persons_accredited_for_access_to_european_parliament_premises": "", "registration_date": "02/02/2015", "estimate_of_costs_absolute_amount": "", "website_address": "http://otsuka-onpg.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "M\u00fcnchen", "membership": "", "head_office_post_code": "80636", "position": "Direktor", "financial_year_start_date": "01/01/2017", "head_office_country": "Germany", "number_of_ep_accredited_persons": "", "relevant_communication": "", "financial_year_end_date": "01/12/2017", "lat": "48.1428413", "estimate_of_costs_as_a_range": "0-9999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "GmbH", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "Otsuka Novel Products GmbH (ONPG), based in Munich/Germany, was founded by the global Otsuka-group in 2010. The main focus of the company is the therapeutic area of tuberculosis. ONPG is Marketing Authorization Holder in Europe for Deltyba, a medicine for the treatment of multidrug-resistant tuberculosis (MDR-TB). Deltyba was approved for use in the EU in April 2014.", "belgium_office_city": "", "head_office_phone": "(+49)206020500"}